Piperlongumine dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Piperlongumine is a compound from long pepper. A 2016 lab test found it kills worn-out human skin cells in a dish. Everything published on this is in cells or rats. No study in people was found, for any use.
Evidence grade for Piperlongumine: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 1 animal study, 3 lab studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
1 animal study, 3 lab studies, no human study
2 effects reported, 2 unwanted, by people using it, not a trial
Goal pages: Injury, healing and recovery, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Piperlongumine is a compound from long pepper. In a dish, it kills worn-out human cells. It is sold as a lab chemical, and long pepper extracts are sold as supplements. It is not approved for anything.
What people take it for
- Clearing worn-out cells.
- Joint health.
- Slowing ageing.
What studies in people showed
Nobody has tested it in people. There is no study in people of any kind, for any use. And since nobody can patent a plant, nobody is likely to pay for one. In rats, it slowed knee arthritis in one 2026 study. In a dish, it killed worn-out human skin cells more than healthy ones.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- The part of the molecule that kills worn-out cells is reactive chemistry, and its safety in people has never been checked.
- Long pepper extracts do not tell you how much piperlongumine is inside.
Where these come from: The safety points are from this page. There are no studies in people and we have no forum reports.
My bottom line
A dish and a rat are not you. I would not take a reactive chemical nobody has tested in a person.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Joint and knee pain1 animal or lab study
35 of the 36 indexed goals have no study of any kind behind Piperlongumine
No study in people, animals or cells on this page reports a result for these. That does not prove Piperlongumine does nothing for them. It does mean anything you have heard about Piperlongumine and one of these did not come from a study cited here.
Show full evidence
What is Piperlongumine?
Piperlongumine is a compound from long pepper. A 2016 lab test found it kills worn-out human skin cells in a dish. Everything published on this is in cells or rats. No study in people was found, for any use.
Piperlongumine is a natural compound from the long pepper plant, Piper longum.
Nobody has tested it in people. A search of the published record found no study in people, no study of how the body handles it, and no registered study, for worn-out cells or anything else. No clean-up drug has improved health in a proper study in people, and piperlongumine has never reached a study in people at all.
In rats, a 2026 study found it cut signs of worn-out cells in knee joint tissue and slowed knee arthritis. The same study used cells taken from people having knee surgery, but only in a dish.
In a dish, it came from the same University of Florida lab screen that found navitoclax. It killed worn-out human skin cells more than healthy ones, however the cells had been worn out: by radiation, by dividing too many times, or by a cancer gene. Later chemistry work showed which part of the molecule does the killing. Some changed versions worked better than the original.
How does Piperlongumine work?
Shown in human cells in a dish: piperlongumine makes worn-out skin cells die off, and one reactive part of the molecule is needed for that. It works better paired with navitoclax in a dish. In rats, it cut signs of worn-out cells in joint tissue. Nobody knows how it works in a person, because nobody has been given it.
What have studies in people found about Piperlongumine?
None found. No study in people, no study of how the body handles it, and no registered study, for any use. Tests on cells taken from patients are lab work, not proof about the drug in people.
What this does not tell you: With no dosing data in people, nobody knows how much gets absorbed, what blood levels you can reach, or whether the levels that kill worn-out cells in a dish can be reached in a person. The reactive part of the molecule that kills worn-out cells is also the kind of chemistry that can harm healthy tissue. Its safety in people has not been checked.
The state of the research
Piperlongumine comes from a plant. That means nobody can own it, so no company has a business reason to pay for the studies that would show what it does in people. That is a fact about money, not a verdict on the science. It cuts both ways. Without studies, nobody would spot harm or uselessness either. And the reactive chemistry that kills worn-out cells is the kind of chemistry that usually needs safety data in people before anyone takes it.
The research on it as a clean-up drug is small, recent, and mostly from the lab that found it. The arthritis result is one rat study from 2026, and nobody has repeated it.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 1 animal study, 3 lab studies in a dish and 1 review. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 5 sources here are studies in people.
- Animal study · done in animals120%
- Lab (cells in a dish) · cells or tissue360%
- Review of studies · sums up other studies120%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 5 different years, 2016 to 2026, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Piperlongumine, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Review of studies2019Emerging senolytic agents derived from natural products
A review that groups piperlongumine with other plant compounds said to clear worn-out cells, like quercetin and fisetin. It covers animal and lab work. It has no results in people, because there are none for piperlongumine.
Review placing piperlongumine among the plant-derived senolytics alongside quercetin and fisetin. A review of preclinical work; it does not report human trial data, because there is none for piperlongumine.
- Animal study2026Piperlongumine attenuates knee osteoarthritis progression by eliminating senescent meniscus cells and chondrocytes
In rats. Piperlongumine cut signs of worn-out cells in knee tissue and slowed knee arthritis. The researchers also tested cells taken from people with arthritis, but only in a dish. No patients were treated.
Rat osteoarthritis model, with supporting experiments in meniscus cells and chondrocytes from patients with osteoarthritis. Piperlongumine reduced p16 and p21 and senescence-associated secretory factors and slowed disease progression in the rats. The human component is cells in a dish, not treated patients.
- Lab (cells in a dish)2016Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
In a dish. Piperlongumine killed worn-out human skin cells more than healthy ones, whether they were worn out by radiation, by dividing too many times, or by a cancer gene. It worked better paired with navitoclax. This is the first clean-up result for it, and it is in cells in a dish.
Cultured human WI-38 fibroblasts. Piperlongumine preferentially killed senescent cells after radiation, replicative exhaustion or oncogenic Ras expression, by apoptosis, without requiring induction of reactive oxygen species, and synergised with ABT-263. This is the originating senolytic finding and it is in cell culture.
- Lab (cells in a dish)2018Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation
In a dish. Chemists changed parts of the molecule to see what mattered. One reactive part was essential for killing worn-out cells. Some changed versions worked better than the original.
Structure-activity work in cells. Modifications to the trimethoxyphenyl ring were tolerated; the Michael acceptor on the lactam ring was essential for senolytic activity. Some analogues had improved potency or selectivity.
- Lab (cells in a dish)2024Piperlongumine regulates genes involved in the skin barrier in epidermal keratinocyte HaCaT cells
In a dish. Work on human skin cells looking at genes for the skin's protective barrier. It has nothing to do with worn-out cells. It is here because it is typical of this compound's research: cells, not people.
Human keratinocyte cell line. Gene expression work on skin barrier genes, unrelated to senescence, included here because it is representative of the compound's literature: cells, not people.
Common questions
What is the Piperlongumine dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 1 animal study, 3 lab studies, no human study
Is Piperlongumine FDA-approved?
Not approved for any use. We found no registered human study. It is sold as a research chemical. It is also found in long pepper extracts sold as supplements, but those do not give a known dose of the pure compound.
Has piperlongumine been tested in people?
No study of piperlongumine in people was found, for worn-out cells or anything else, and no study is registered. Tests on cells taken from patients are lab tests, not studies in people.
Is long pepper extract the same thing?
No. Long pepper extracts sold as supplements contain piperlongumine along with many other compounds, in amounts nobody has measured. The published research used the pure compound at set strengths on cells in a dish.
What has piperlongumine actually been shown to do?
In a dish, it killed worn-out human skin cells more than healthy ones, and worked better paired with navitoclax. In rats, it cut signs of worn-out cells in joints and slowed knee arthritis. That is all the proof there is.